All News
FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk
Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes.
Read ArticleAnakinra May Attenuate Stroke Outcomes
The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke.
Read ArticleCARES Study- More CV Deaths with Febuxostat
The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.
Read Article2017 Rheumatology Year in Review
This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017. In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.
Read ArticleProbenecid Benefits Heart Failure
In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation.
Read ArticleEqual Cardiovascular Risks in Hypertensive Patients Treated with Selective and Nonselective NSAIDS
A Taiwanese study of 55,629 hypertensive patients shows no increased risk of major cardiovascular events comparing outcomes of patients started on COX-2 selective NSAIDs compared with nonselective NSAIDs (including ibuprofen, diclofenac and naproxen).
Read ArticleCalcium and Vitamin D Do Not Increase Cardiac Events/Death
An analysis of the UK Biobank study found no link between calcium/vitamin D supplementation and incident cardiovascular events/deaths in a large prospective study of 475,255 men and women aged 40 to 69 years.
Read ArticleThe RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read ArticleRWCS Day 2 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features Drs. Martin Bergman, Jack Cush, Rachel Tate, Phil Aleksiejuk, Shubha Kollampare, Orrin Troum, and Alvin Wells. Listen here or on Stitcher, iTune, iPhone, Soundcloud or Google play.
Read ArticleNailfold Capillaroscopy Portends Prognosis in Systemic Sclerosis
Two reports underscore the importance of nailfold capillaroscopy (NFC) in scleroderma and have shown that nailfold capillary drop out was significantly associated with mortality in systemic sclerosis.
Read ArticleAbatacept Shows Promise for RA-ILD
Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.
Read ArticleInefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD
EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged
Read ArticleESRD Death Declines in Vasculitis Patients
In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.
Read ArticleLess Cardiovascular Risk with Abatacept in Rheumatoid Arthritis
A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).
Read ArticleStroke Risk Highest in the First Year of Lupus (Best of 2017)
Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year.
Read ArticleThe RheumNow Week in Review - 22 December 2017
Dr. Jack Cush reviews highlights and news from the past week on RheumNow.com.
Read ArticleCardiac Disturbances Increased in Spondyloarthritis
A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.
Read ArticleCochrane Review: Calcium Channel Blocker Efficacy in Raynaud's
The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.
Read ArticleFDA Approves Mepolizumab for Churg-Strauss (EGPA)
The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA.
Read ArticleThe RheumNow Week in Review - 8 December 2017
Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.
Read Article